Supreme Court Petitioned to Reinstate Mail-Order Access for Mifepristone

Danco Laboratories has requested the U.S. Supreme Court to overturn a recent ruling by the 5th U.S. Circuit Court of Appeals that prohibits the mail-order distribution of mifepristone, an abortion pill. This ruling, effective immediately, disrupts the FDA's 2023 guidelines aimed at easing access to the medication, causing significant confusion for patients and healthcare providers. The case, initiated by Louisiana's Attorney General, raises questions about the standing of states to challenge FDA approvals. Danco's lawyers argue that the decision creates immediate chaos for patients seeking timely medical care, particularly as many may be unable to secure in-person appointments. The Supreme Court's decision on this emergency application could have widespread implications for abortion access across the country.

Key Details: • Emergency application filed on May 2, 2026, by Danco Laboratories. • 5th U.S. Circuit Court's ruling blocks FDA's 2023 guidelines immediately. • Patients may face confusion and delays in obtaining mifepristone. • Louisiana's Attorney General is a plaintiff in the case.